Physician profile
Gina-Marie Barletta
NPI 1417921131
$9,957.28
in general payments reported to CMS, 2019-2025
12 companies · $6,628 in 2025
The $6,628 reported for 2025 was more than what 90% of Pediatric Nephrology providers received nationally (typical 2025 total: $131).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.29 · 2020: $21.26 · 2021: $2,724 · 2023: $122 · 2024: $372 · 2025: $6,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $3,750 · Travel and Lodging: $2,124 · Food and Beverage: $1,023 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $3,750.00 |
| Travel and Lodging | $2,123.96 |
| Food and Beverage | $1,023.21 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $225.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pierre Fabre Pharmaceuticals, INC. | $4,698.60 | 2025 | |
| Alnylam Pharmaceuticals INC. | $2,805.15 | 2021-2023 | Oxlumo |
| Bayer Healthcare Pharmaceuticals INC. | $1,762.62 | 2025 | |
| Novartis Pharmaceuticals Corporation | $225.00 | 2024 | |
| Apellis Pharmaceuticals, INC. | $166.63 | 2025 | Empaveli |
| Novo Nordisk Health Care Ag | $122.83 | 2024 | |
| Mallinckrodt Enterprises LLC | $49.08 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $46.20 | 2019-2021 | |
| Boston Scientific Corporation | $24.60 | 2024 | |
| Leadiant Biosciences, INC. | $21.26 | 2020 | |
| Alexion Pharmaceuticals, INC. | $18.57 | 2019 | |
| Novo Nordisk INC | $16.74 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina-Marie Barletta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.